STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

2021/02/20 by Dan Turner, Amanda Ricciuto, Ayanna Lewis +23 · 34 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Autoimmune and Inflammatory Disorders Research #Inflammatory Bowel Disease #Natural Compounds in Disease Treatment

paper · doi:10.1053/j.gastro.2020.12.031

openalex publication_date 2021/02/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Cited by

• A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn’s Disease
• Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
• How I Do It: Cross-sectional Imaging in Small-Bowel Crohn Disease and Ulcerative Colitis
• miRNA-loaded biomimetic nanoparticles orchestrate gut microbe to ameliorate inflammatory bowel disease
• Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
• Healthcare professionals’ knowledge, attitudes, and practice with addressing sexual health among people living with inflammatory bowel disease: A UK cross-sectional survey
• Multimodality Imaging of Small Bowel Crohn Disease
• Integrating intestinal ultrasound into routine clinical care improves prediction of biochemical disease activity in pediatric inflammatory bowel disease
• Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn’s disease using summary level data and its application to model-informed precision dosing
• Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. [europepmc]
• Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. [europepmc]
• Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. [europepmc]
• Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. [europepmc]
• A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. [europepmc]
• Calprotectin: from biomarker to biological function. [europepmc]
• Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. [europepmc]
• Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. [europepmc]
• Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. [europepmc]
• The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. [europepmc]
• Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice? [europepmc]
• Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. [europepmc]
• Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. [europepmc]
• Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. [europepmc]
• Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. [europepmc]
• A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. [europepmc]
• Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. [europepmc]
• Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. [europepmc]
• Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. [europepmc]
• Biopsy and blood-based molecular biomarker of inflammation in IBD. [europepmc]
• Implications of the changing epidemiology of inflammatory bowel disease in a changing world. [europepmc]
• Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease. [europepmc]
• Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics. [europepmc]
• Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. [europepmc]
• Quality indicators for colonoscopy. [europepmc]